SHSE:688062 (China)
Â
Class A
Â¥
21.36
(-2.95%)
Aug 23
Mabwell (Shanghai) Bioscience Co Ltd (SHSE:688062) Stock News, Headlines & Updates
Mabwell (Shanghai) Bioscience Co Ltd Stock News from GuruFocus
- 1
Aug 23, 2024
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
PRNewswire • 10:00am
Aug 12, 2024
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
PRNewswire • 10:00am
Jul 16, 2024
FDA Grants Orphan Drug Designation to 7MW3711
PRNewswire • 10:00am
Jul 15, 2024
Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC
PRNewswire • 10:00am
Jul 12, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news